Alkem Laboratories Limited (ALKEM) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹5,398.5 (+1.78% day change)
Key ratios
- P/E ratio
- 28.04
- P/B ratio
- 4.58
- ROE (%)
- 16.66
- ROCE (%)
- 16.3
- Debt/Equity
- 0.15
- Dividend yield (%)
- 0.97
- Market cap (₹ Cr)
- 64,547.17
Forensic checks
Piotroski F-Score: 3/9 · Altman Z-Score: 10.79 · Beneish M-Score: -2.15
InvestSights quality score
71.2/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- EBITDA margin: guided 17%, delivered 17.7% (FY24) — exceeded guidance
- Domestic revenue growth: guided 8–9%, delivered 5.9% (Q3 FY25) — missed guidance
Latest earnings call (Q1 FY27)
AI summary: The central signal is that Alkem’s core India branded business remains healthy, but consolidated earnings quality is being diluted by new-business investment and a weak US volume environment. Branded generics grew 12%, India could finish FY27 at close to 12% growth, and management maintained gross-margin guidance of 66.5% to 67%. However, Enzene US is carrying around ₹60…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.